We are international

Myeloma Minute
July 31, 2014
July 31, 2014
Share the Minute Facebook Tweet!
Clinical Trials
Donate to the IMF

This week's question: What are the important aspects of different types of imaging, such as regular x-rays, MRI, CT, and PET?

Upcoming Events

August 22 - 23, 2014
Patient & Family Seminar
Los Angeles, California

Thursday, August 28, 2014
Living Well with Myeloma: Understanding the Immune System and Lab Values in Myeloma


Frontline Therapy and MRD: Exciting New Data from France

Minimal residual disease (MRD) measurement through flow cytometry was shown to be a meaningful predictor in a frontline myeloma study published this month in the Journal of Clinical Oncology. In his blog, IMF Chairman Dr. Brian Durie explains that patients who achieved MRD-negative status remain in remission after a median follow-up of three years. This study “points the way to incorporation of MRD testing by flow cytometry into tailored approaches to achieve the very best results with therapy throughout the course of disease,” said Dr. Durie. READ MORE


IMF Supports Support Group Leaders During 15th Annual Summit

Nearly 100 myeloma support group leaders gathered in Dallas, Texas over the weekend for the IMF's 15th Annual Support Group Leaders Summit. "During the year, these leaders give their all to their myeloma support groups," said Robin Tuohy, IMF Senior Director of Support Groups. "At the Summit, we give THEM as much as we can so they can share with their members the latest news about myeloma treatment, clinical trials, best practices for running a support group, and - perhaps most important of all - a chance to create lifelong bonds with fellow leaders across the nation." Leaders were instructed in the practice of tai chi (right) as a relaxation tool to pass along to their members. READ MORE

New IMF Publication: Understanding Serum Free Light Chain and Serum Heavy/Light Chain Assays
A new IMF publication is available with important information on two tests used to diagnose and monitor myeloma: the serum free light chain assay (Freelite®) and the serum heavy/light chain assay (Hevylite®). The Freelite test quantifies monoclonal protein and the Hevylite test quantifies intact heavy and light chain pairs. Since Freelite and Hevylite are independent biomarkers of disease activity, it is important to monitor myeloma with both tests. CLICK HERE to read more in Understanding Serum Free Light Chain and Serum Heavy/Light Chain Assays.
Kentucky Oral Anticancer Treatment Law
Kentucky cancer patients are assured affordable access to their oral anticancer drugs thanks to the work of the IMF and other organizations on a new law that limits copays to $100 per month. The IMF and myeloma patients played an important role in introducing the bill to Kentucky's legislature and attracting support for the legislation before Gov. Steve Beshear signed it into law. To read more about the Kentucky law and ongoing work on federal bills, CLICK HERE.


Living Well with Myeloma: Understanding the Immune System and Lab Values in Myeloma

The IMF's popular Living Well with Myeloma teleconference series returns on August 28th, with "Understanding the Immune System and Lab Values in Myeloma." The discussion and Q&A will be led by IMF Nurse Leadership Board member Ann McNeill, RN, MSN, APRN-C, Multiple Myeloma Division, Hackensack University Medical Center. CLICK HERE to register for the free teleconference, which will be held on Thursday, August 28th at 7 pm ET/ 4 pm PT. To listen to archived recordings of past Living Well with Myeloma teleconferences, CLICK HERE.

Join Our Mailing List

12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
IMF Hotline: 800-452-2873 or 818-487-7455
Privacy Policy | Unsubscribe

 related articles